ClinicalTrials.Veeva

Menu
F

Fresno Clinical Research Center | Fresno, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Selonsertib
MGL-3196
LY3298176
Relamorelin
Obeticholic Acid
HTD1801
Firsocostat
Cilofexor
Resmetirom
Elafibranor

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 14 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

This is a safety study to evaluate BOS-580 administered subcutaneously with repeated dosing over 12 weeks in Part A or 24 weeks in Part B. Part C is...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

Trial sponsors

Gilead Sciences logo
Madrigal Pharmaceuticals logo
Allergan logo
Boston Scientific logo
Genfit logo
H
I
Lilly logo
Mirum Pharmaceuticals logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems